Business Wire

NJ-OPEX

11.3.2024 15:01:27 CET | Business Wire | Press release

Share
Meet the Next Generation of Automated Sortation and Order Retrieval―Introducing OPEX® Sure Sort® X with OPEX Xtract™

OPEX® Corporation, a global leader in Next Generation Automation for almost 50 years, today announced the launch of its newest automated sorting and order retrieval solutions―OPEX Sure Sort® X with OPEX Xtract™. These innovative technologies were officially unveiled by company leadership at MODEX 2024, the largest manufacturing and supply chain trade event, held this year at the Georgia World Congress Center in Atlanta.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240311187962/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

OPEX® Sure Sort® X with OPEX Xtract™ (Photo: Business Wire)

OPEX Sure Sort X represents the next generation of high-speed, automated sorting. It is the most robust industrial sorting solution available in the market, unmatched in terms of its compact footprint, performance rates, and cost-effectiveness. This universal system can handle nearly 100% of customer-sortable items weighing up to 20 pounds (9 kg), and sort items into a configurable array of mixed bin sizes and types.

When Sure Sort X is paired with Xtract―OPEX’s revolutionary new automated order retrieval system―the task of retrieving totes and transferring their contents into shipping containers is now fully automated, as well. The result is a one-touch solution that can eliminate the need to manually sort and transfer boxes downstream.

"OPEX remains dedicated to innovations that align with the evolving demands of the market," stated Alex Stevens, President of Warehouse Automation at OPEX. "We have received feedback from our customers that they want one integrated solution to sort, retrieve, and automatically get the product into its final container. Our new solutions, Sure Sort X and Xtract, are a response to those requests. This cutting-edge technology is designed to automate multiple manual tasks with a simple, one-touch solution.”

Developed based on feedback from the international business community, Sure Sort X applies OPEX Corporation’s innovative, industry-leading Sure Sort technology, introduced in 2017. With its enhanced product handling capabilities, Sure Sort X is the single most versatile and configurable sorting solution available. It can handle items 60 percent smaller, nearly 20 percent larger, and up to 300 percent heavier than its predecessor, all while maintaining a consistent throughput of up to 2,100 items per hour.

The system’s iBOT® delivery vehicles utilize sophisticated motion algorithms that allow them to maneuver throughout the system efficiently, with the ability to change destination in real time while in transit. These iBOTs can drive in and out of the system while Sure Sort X continues to run, ensuring the highest level of uptime and availability. In addition, Sure Sort X can operate in both chilled and ambient environments. Installation can occur in as little as one week.

OPEX Xtract can be added to any Sure Sort X system by introducing retrieval iBOTs to work in conjunction with the traditional sortation iBOTs found in Sure Sort X. Xtract iBOTs move in a loop that has both horizontal and vertical segments within the Sure Sort X aisle, and can handle up to 200 extracted totes per hour. All of the iBOTs are self-charging and can easily be added to or removed from the system.

The system can retrieve standard totes or can be outfitted with Xtract totes, which are uniquely designed to transport items from the sort location to any available roller, v-chute, transfer (RVT) module. If these totes are used, once all products for a relevant order have been deposited into the Xtract totes, each tote is retrieved and transported to the RVT module, where the tote door opens and releases the items into the final shipping box or order container.

Soon after its unveiling in the US at MODEX, Sure Sort X will make its European debut at the LogiMAT expo in Stuttgart, Germany, on March 19, 2024, at the OPEX exhibit in Hall 7, Stand 7D53.

Sure Sort X and Xtract join the existing Warehouse Automation portfolio at OPEX, which includes Sure Sort®—the industry-leading, high-speed, small-item robotic sorting system; Perfect Pick®, a robotic goods-to-person picking solution that dramatically improves speed, efficiency, and reliability, and Infinity®―the most advanced goods-to-person solution available in warehouse automation. All are custom configured for each client and designed to completely transform supply chain infrastructure.

For nearly five decades, OPEX Corporation has served as a trusted partner, collaborating closely with clients to develop customized, scalable solutions that transform how business is conducted. OPEX continuously reimagines automation technology to help clients solve their most significant business challenges, today and in the future.

About OPEX

OPEX® Corporation is a global leader in Next Generation Automation, providing innovative, unique solutions for warehouse, document and mail automation. With headquarters in Moorestown, NJ, USA—and facilities in Pennsauken, NJ; Plano, TX; France; Germany; Switzerland; the United Kingdom; and Australia—OPEX has more than 1,600 employees who are continuously reimagining and delivering customized, scalable technology solutions that solve the business challenges of today and in the future.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240311187962/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye